本帖最后由 老马 于 2013-3-13 13:43 编辑 ! d" B. w3 H, E0 l1 ~
' x) O- |2 w$ K( Y5 q健择(吉西他滨)+顺铂+阿瓦斯汀
+ e1 s* p9 P9 U8 N) a, d Gemzar +Cisplatin + Avastin& z0 p. G5 }5 G# {. e
http://annonc.oxfordjournals.org/content/21/9/1804.full. e3 ]0 V# g. f$ G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 n# ]) d8 r2 D; S/ j. oPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. & O% ?) g1 h; s% h
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ) N: N( D8 _& W
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 833)
# N$ ~3 f2 O" r( P. w, z
华为网盘附件:2 g% Z. t1 m$ B s. [
【华为网盘】ava.JPG5 b8 x( {0 Z( ^5 X- g# ?; W
|